جستجوی استاد راهنمای دانشگاهی

• Immunology
• Genomics
• Multiomics Analysis
• +۳ مورد دیگر

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

Manuela Zucknickمشاهده پروفایل

استاد

• Statistical learning for translational cancer research
• Personalized cancer therapies
• Multi-omics data integration
• +۷ مورد دیگر

Manuela Zucknick is Professor and Director of the Oslo Centre for Biostatistics and Epidemiology at the University of Oslo's Faculty of Medicine, Department of Biostatistics. Her research integrates statistical learning with translational cancer research to advance personalized medicine through multi-omics data integration. PhD Biostatistics, Imperial College London (2008) MSc Bioinformatics, Imperial College London (2004) Diplom Statistik, University of Dortmund (2003) Her research focuses on Bayesian methods for integrating heterogeneous data sources in cancer research, particularly for drug response prediction in pharmacogenomic screens and patient prognosis. She develops structured high-dimensional regression models for 'large p, small n' problems in molecular medicine, with emphasis on incorporating prior biological knowledge into risk prediction frameworks. Her work bridges statistical methodology with clinical applications in personalized cancer therapies. Her recent publications demonstrate consistent contributions to multi-omics integration and survival modeling across diverse clinical contexts including cancer, pregnancy complications, and rheumatoid arthritis. The research shows strong methodological innovation in handling high-dimensional biological data while maintaining clinical relevance. Through the Oslo Centre for Biostatistics and Epidemiology, she leads collaborative projects spanning oncology, obstetrics, and rheumatology. Her work frequently involves designing statistical frameworks for pharmacogenomic screens and developing tools for biomarker discovery in complex disease settings.

• Proteomics
• Biomarker Discovery
• Autoimmune Diseases
• +۳ مورد دیگر

Allan Stensballe is an Associate Professor at Aalborg University's Department of Health Science and Technology, affiliated with The Faculty of Medicine. His research focuses on translational pain neuroscience and precision health, particularly in biomarker discovery and proteomics. He leads projects such as the Danish C-HPP node under HUPO and the PLATO National Platform for Proteomics and Biomedical Imaging. His work integrates clinical and basic science to address autoimmune diseases, infectious disorders, and transgender health. Key research interests include proteomic profiling of inflammatory conditions (e.g., rheumatoid arthritis, spondyloarthritis), autoantibody-driven diagnostics, and translational applications of proteomics in precision medicine. He has contributed to studies on biomarkers for prosthetic joint infections, gender-affirming hormone therapy outcomes, and microbial pathogenesis (e.g., Klebsiella pneumoniae). Dr. Stensballe has secured funding for 24 active and completed projects, including collaborations with industry partners via EUROSTARS. His publications span 238 peer-reviewed articles, emphasizing biomarker discovery, proteomics, and clinical translational research. He actively contributes to conferences, serves on review committees, and supervises 7 PhD students. His work aligns with UN SDGs related to health and well-being (SDG 3) and partnerships for the goals (SDG 17). Labs/Teams: Translational Pain Neuroscience and Precision Health (TPNP) group, Neuroboost initiative.

Morten Bilde Simonsenمشاهده پروفایل

استادیار

• Biomechanics
• Osteoarthritis
• Gait Analysis
• +۷ مورد دیگر

Morten Bilde Simonsen is an Assistant Professor at Aalborg University in the Department of Materials and Production, affiliated with the Section of Applied Systems Research and Biomechanics within the Faculty of Engineering and Science. His research focuses on biomechanics, musculoskeletal disorders, and the application of advanced technologies for clinical assessment and intervention. He holds a PhD awarded in April 2021. His work integrates biomechanical modeling, gait analysis, and proteomics to address conditions like knee osteoarthritis, rheumatoid arthritis, and pediatric obesity. A key project is the MathKOA initiative (2022–2027), a Novo Nordisk Foundation-funded effort developing predictive models for knee osteoarthritis. Research interests include gait mechanics, HIIT in youth obesity, and the biomechanical impact of interventions like foot orthoses. He has received awards such as the 2022 Best Presentation at the Regions Hospital Northern Jutland Symposium and the 2018 Danish Society of Biomechanics Student Award. His grants include leadership roles in multi-disciplinary projects combining clinical and engineering approaches. Collaborations span musculoskeletal modeling, sensor technology validation, and translational research in chronic pain and joint dysfunction. He is actively involved in lab-based studies on gait kinematics, biomarker identification, and exercise intervention efficacy.

• Rheumatology
• Immunology
• Autoimmune Diseases
• +۳ مورد دیگر

Dr Alessandra Nerviani is a Clinical Research Fellow at the William Harvey Research Institute, Queen Mary University of London. Her work focuses on rheumatoid arthritis (RA) and other autoimmune conditions, with a particular emphasis on synovial tissue pathobiology, biomarker discovery, and treatment response mechanisms. She contributes to clinical trials like the R4RA trial, investigating therapeutic strategies such as rituximab and tocilizumab. Her research integrates molecular profiling, histopathology, and cellular analysis to define disease subtypes and improve patient stratification for targeted therapies. Key research interests include TAM receptors (Axl/MerTK), synovial inflammation pathways, and the role of B cells and macrophages in disease progression. She has published extensively on synovial tissue signatures, biomarkers for disease activity, and mechanisms underlying treatment resistance in RA and related conditions. Collaborative projects involve multi-omic approaches to identify novel therapeutic targets and improve clinical outcomes for autoimmune patients. Grants: Involved in R4RA trial funding, biomarker discovery initiatives, and drug mechanism studies. Labs: Works within the William Harvey Research Institute's rheumatology and immunology research groups.

Felice Rivelleseمشاهده پروفایل

مدرس ارشد

• Rheumatology
• Immunology
• Precision Medicine
• +۷ مورد دیگر

Dr. Felice Rivellese is a Clinical Senior Lecturer at Queen Mary University of London's Faculty of Medicine and Dentistry, affiliated with the Experimental Medicine & Rheumatology department. He leads the EMR Clinical Research Team, focusing on precision medicine strategies in musculoskeletal health. His academic roles include Principal Investigator (PI) for the EU-funded MDR-RA initiative and NIHR-supported projects. Education: MD from University of Naples Federico II and PhD in Clinical Pathophysiology/Experimental Medicine from Queen Mary University of London. He has held research fellowships at Leiden University and the Centre of Experimental Medicine & Rheumatology in London. Research focuses on rheumatoid arthritis (RA) mechanisms, synovial biology, and precision medicine. Key areas include multi-drug resistant RA, synovial B cells, and clinical trial design. He leads major trials like MDR-RA and 3TR, using molecular profiling and histopathology to inform treatment strategies. Awards include Marie-Curie Fellowship, NIHR Transitional Research Fellowship, and EU grants. His work spans clinical trials, bioinformatics, and translational research, with collaborations across Europe. He chairs EMEUNET committees and serves on EULAR and BSR boards. Current projects involve understanding stromal cells' role in MDR-RA, socioeconomic impacts on disease outcomes, and developing biomarker-driven therapies. His team includes PhD students and clinical practitioners working on synovial pathotypes and treatment resistance.

Maya Buchمشاهده پروفایل

استاد بالینی

• Rheumatology
• Cardiovascular Pathology
• Immune-Mediated Inflammatory Diseases
• +۵ مورد دیگر

Maya Buch is a Clinical Professor of Rheumatology and Director of Experimental Medicine at the University of Manchester's Centre for Musculoskeletal Research. She holds leadership roles including NIHR Senior Investigator, Co-lead of the NIHR-BHF Cardio-Immune partnership, and National Lead for the NIHR Bioresource in systemic sclerosis. Her research focuses on precision medicine in rheumatoid arthritis, cardiovascular complications of immune diseases, and improving therapeutics for systemic sclerosis. NIHR Manchester Biomedical Research Centre: Leads the Advanced Diagnostics & Therapeutics Catalyst cluster Chief Investigator of the MRC-BHF UK CARDIO-IMID partnership Chair of the MRC-NIHR Efficacy, Mechanism, Evaluation Programme (2025–2027) Research Themes: Precision medicine in RA (PRECISE-RA), cardiovascular pathology in IMIDs (CARDIO-IMID), and systemic sclerosis outcomes. Key Projects: PHOSP-COVID consortium, BHF Centre for Research Excellence, and NIHR Versus Arthritis collaboration. Her work contributes to SDG3 (Good Health) and SDG10 (Reduced Inequalities). Over 146 publications focus on rheumatology, cardiovascular comorbidity, and immunotherapies. Notable articles include studies on corticosteroid use in severe COVID-19 and biomarkers in refractory RA. Scientific Leadership: 3 active grants, including £multi-million initiatives Collaborations: Global networks in rheumatology and cardiovascular medicine Labs/Teams: Leads experimental medicine teams at Manchester and collaborates with Leeds University as a Visiting Professor.

Aedin Culhaneمشاهده پروفایل

استاد

• Cancer Genomics
• Bioinformatics
• Single Cell Biology
• +۸ مورد دیگر

Aedin Culhane is a Professor of Biomedical Sciences (Cancer Genomics) at the University of Limerick School of Medicine. She leads the Limerick Digital Cancer Research Centre and co-leads the all-island eHealth-Hub for Cancer. Her expertise spans computational oncology, multi-omics data integration, and clinical bioinformatics, with over 20 years of experience in cancer genomics, including roles at the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston, USA. Education: PhD in Cloning and Characterisation of Interleukin-18 in rat brain, University of Manchester Research Interests: Cancer computational genomics, digital health, single-cell genomics, spatial biology, tumor microenvironment, immune-oncology, and open science initiatives like Bioconductor and OHDSI. She focuses on algorithm development for integrative multi-omics data analysis and translational oncology, including tumor drug resistance mechanisms and CAR-T cell therapies. Recent Article Trends: Her work emphasizes spatial profiling of cancer microenvironments, CAR-T cell engineering, and genomic minimal datasets for precision oncology. Key themes include immune response modulation, Myc activity regulation in treatment persistence, and CRISPR-based functional genomics. Awards: Young European Research Universities Network (YERUN) Open Science Award (2023) Bioconductor Community Award (2021) Grants & Collaborations: Leads the €730,000 Chan Zuckerberg Initiative-funded eHealth-Hub for Cancer. Active in the 1+ Million Genomes Program and Genomic Data Infrastructure (GDI) projects. Collaborates internationally in spatial profiling and multi-omics integration through hackathons and open-source initiatives. Labs & Teams: Directs the Limerick Digital Cancer Research Centre, a hub for AI-driven cancer research and translational genomics. Engages with global networks like the Human Cell Atlas and National Spatial Profiling Platform.

Dan Tongeمشاهده پروفایل

مدرس ارشد

• Bioinformatics
• Molecular Sequencing
• Transcriptomics
• +۳ مورد دیگر

Dr. Dan Tonge is Senior Lecturer in Biosciences at Keele University's School of Life Sciences and serves as Director of Postgraduate Research. He is the Designated Individual for Keele's Human Tissue Authority research-sector license. With expertise in molecular sequencing and bioinformatics, his research employs next-generation sequencing technologies for understanding human health and disease mechanisms. His current projects include characterizing extracellular vesicle miRNA cargo, biomarker identification for cell transplantation therapies, de novo transcriptome assembly, and microbiome analysis using multi-platform sequencing (Illumina, PacBio, Nanopore). He leads bioinformatics for several major grants including BBSRC Engineering Biology and EPSRC awards, with international collaborations in China and South Africa supported by a Royal Society Travel Grant.

• Biomaterials
• Tissue Engineering
• Bone Regeneration
• +۵ مورد دیگر

Pengzhen Zhuang is a researcher at the Faculty of Natural Sciences and Technology at Åbo Akademi University, working within the InFLAMES flagship project focused on immune system-driven solutions for health. Their work bridges biomaterials and regenerative medicine, targeting bone repair, osteoarthritis treatment, and antimicrobial resistance. Active in UN Sustainable Development Goals: Poverty Eradication, Health Equity, and Responsible Innovation Key collaboration networks across 12 institutions in Finland, China, and India Research spans three major domains: Biomaterial-Immune Interactions: Designing scaffolds that modulate macrophage behavior through mitochondrial regulation and metabolic homeostasis Antimicrobial Systems: Developing CO gas delivery platforms and ROS-generating materials to combat drug-resistant biofilms Joint Regeneration: Creating hydrogel microspheres for osteoarthritis treatment and subchondral bone repair Current research trends show a focus on: Multi-functional scaffold design (7/15 articles) Immune microenvironment engineering (6/15 articles) Chronological release systems (4/15 articles) 3D printing applications in bone regeneration (3/15 articles) As a collaborator in the MADNESS Center of Excellence for antimicrobial resistance, Zhuang contributes to advancing material-based solutions against persistent infections. Their work demonstrates strong interdisciplinary integration of nanotechnology, immunology, and clinical applications.

David Gibsonمشاهده پروفایل

استاد

• Proteomics
• Pharmacogenomics
• Rheumatoid Arthritis
• +۳ مورد دیگر

David Gibson is a Professor of Medicine at the Ulster University School of Medicine , and serves as Research Group Lead at the Personalised Medicine Centre . With a PhD in Cancer Research from Queen’s University Belfast , he has over two decades of experience in proteomics, biomarker discovery, and pharmacogenomics. Specializes in rheumatoid arthritis and inflammatory diseases Developed BloodTrackR for home-based arthritis monitoring Created machine learning tool ATRPred for anti-TNF treatment decisions Current research spans biomarker validation and drug-gene compatibility His work intersects with UN Sustainable Development Goals for Good Health and Well-being (SDG3) . Recent collaborations include institutions in United States (University of Colorado, Denver) and United Kingdom (Queen’s University Belfast). Scientific Awards : 2023: American Association of Immunologists Laboratory Travel Grant 2020: American Association of Immunologists Early Career Grant 2009: Arthritis Research UK Travelling Fellowship 2008: Northern Ireland Science Park Biotech Innovation Award Key teaching areas include Biochemistry , Omics Technologies , and Inflammatory Disease Mechanisms . His publications cover topics from COVID-19 risk prediction to HLA haplotype-drug interactions in arthritis treatment.

Costantino Pitzalisمشاهده پروفایل

استاد

• Rheumatology
• Autoimmunity
• Inflammation
• +۳ مورد دیگر

Professor Costantino Pitzalis is the Versus Arthritis Professor of Rheumatology at the William Harvey Research Institute, part of Queen Mary University of London. He serves as Deputy Director of the William Harvey Research Institute and Head of the Centre for Experimental Medicine and Rheumatology (EULAR Centre of Excellence in Rheumatology 2023-2028). His research focuses on cellular and molecular mechanisms underlying inflammation and autoimmunity in rheumatic diseases, particularly rheumatoid arthritis (RA). He leads the Musculoskeletal Theme of the NIHR Barts Biomedical Research Centre (2022-2027), addressing health inequalities and innovative healthcare delivery. Pitzalis has published over 300 peer-reviewed papers and pioneered stratified, biopsy-driven clinical trials (R4RA and STRAP) funded by NIHR and MRC/VA, which assess drug efficacy across RA stages. His clinical expertise spans immune/inflammatory rheumatic diseases, including psoriatic arthritis, Sjögren’s syndrome, and osteoarthritis. Research themes include synovial tissue pathobiology, biomarker discovery, and translational drug development. Collaborations with industry (e.g., Sanofi, GSK) and academic institutions (e.g., University of Rome, University of Manchester) enhance his work. Pitzalis’ team integrates basic science with clinical trials, aiming to improve patient care through targeted therapies and personalized medicine. Key achievements include identifying synovial pathotypes predictive of treatment response and developing novel diagnostic tools like BioX-CPath. His work emphasizes multi-omics approaches and spatial biology to dissect disease mechanisms. Awards include leadership of EULAR-accredited research centers and contributions to international initiatives like the IMI 3TR project.

Abhinav Acharyaمشاهده پروفایل

دانشیار

• Immune Engineering
• Immunometabolism
• Drug Delivery
• +۵ مورد دیگر

Abhinav Acharya is the Elmer Lincoln Lindseth Associate Professor of Biomedical Engineering at Case Western Reserve University's Case School of Engineering and a member of the Case Comprehensive Cancer Center. His research focuses on immune engineering and immunometabolism, leveraging biomaterials to modulate immune cell metabolism for treating cancer, autoimmune disorders, and chronic inflammation. He holds appointments in both the School of Engineering and School of Medicine, reflecting his interdisciplinary work. Education & Training: PhD in Biomedical Engineering (University of Florida) Postdoctoral Research: Georgia Institute of Technology, UC Berkeley, and University of Pittsburgh Research Interests: Dr. Acharya develops biomaterial systems to engineer immune responses via metabolic pathways. Current projects include metabolite-based polymers for cancer immunotherapy, covalent organic frameworks for immune modulation, and anti-inflammatory strategies for rheumatoid arthritis. His lab explores diseases such as melanoma, traumatic brain injury, and osteoarthritis, with a focus on translational therapies. Publications & Patents: Over 50 peer-reviewed articles and multiple patents (e.g., metabolism-targeted vaccines, wound healing polymers, and probiotic therapies). Recent work includes Nature Communications (2023), Advanced Healthcare Materials (2024), and Biomaterials Science (2022). Grants & Awards: Funding from NSF (CAREER), NIH, and industry partnerships. The lab spun out startups like Immunometabolix LLC for commercializing therapies. Labs & Teams: Runs a multidisciplinary lab with 10+ members, including PhD students, postdocs, and undergraduates. Collaborates with institutions such as Arizona State University and the University of Pittsburgh.

Christos Papaneophytouمشاهده پروفایل

استاد

• Drug discovery
• Cancer therapeutics
• Inflammatory/autoimmune diseases
• +۳ مورد دیگر

Professor Christos Papaneophytou is a full-time Professor at the University of Nicosia (UNIC), holding the additional administrative roles of Associate Dean and Program Coordinator within the School of Life and Health Sciences, Department of Life Sciences. Education: PhD in Biochemistry, Aristotle University of Thessaloniki, 2008 MSc in Biochemistry, Aristotle University of Thessaloniki, 2004 BSc in Chemical Engineering, Aristotle University of Thessaloniki, 2000 Research Interests Prof. Papaneophytou leads an interdisciplinary program that bridges chemical biology, structural biochemistry, and translational medicine. His laboratory focuses on three major pillars: Targeted drug discovery – design and optimization of small-molecule inhibitors against kinases and cytokines implicated in cancer and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. Biomarker development – integration of multi-omics data to identify microRNA and protein signatures enabling early diagnosis of osteoarthritis. Natural antimicrobials – mining plant-derived polyphenols and other secondary metabolites to combat multidrug-resistant pathogens and reduce antibiotic dependence. Publication Trends Between 2022 and 2025, his 15 most recent articles reveal a strategic shift toward translational applications: roughly half investigate novel anti-inflammatory or antiviral agents, while the remainder deploy cutting-edge biophysical and gene-editing tools to dissect metabolic reprogramming in cancer and neuroinflammation. A growing subset explores educational innovation, reflecting his commitment to evidence-based pedagogy in the AI era. Scientific Awards & Recognitions Principal Investigator, H2020 OACTIVE project on osteoarthritis biomarkers Greek State Scholarships Foundation (IKY) fellowship for doctoral studies Editorial Board member, Archives of Industrial Biotechnology Reviewer for Microbial Cell Factories , Combinatorial Chemistry & High Throughput Screening , Biochemical Engineering Journal , and Cellular and Molecular Life Sciences Supervision & Funding Prof. Papaneophytou has extensive experience mentoring undergraduate, master’s, and PhD students. He has successfully secured competitive grants from both international (EU H2020) and national funding bodies, currently directing the multi-institutional OACTIVE consortium aimed at personalised osteoarthritis risk prediction. Laboratory & Teams He heads an active research group within the University of Nicosia’s Department of Life Sciences, equipped with state-of-the-art facilities for protein biochemistry, cell culture, small-animal pharmacogenetic studies, and high-throughput screening. The team collaborates closely with the Cyprus Institute of Neurology and Genetics and multiple European partners to accelerate bench-to-bedside translation.

• Bioinformatics
• Algorithmic Biology
• Natural Computing
• +۴ مورد دیگر

Simone Avesani serves as a Researcher in the Department of Computer Science at the University of Verona's School of Science and Engineering. His academic sector is INFO-01/A - Informatics, where he contributes to the university's research infrastructure through specialized computational approaches to biological data. His research spans Bioinformatics, Algorithmic Biology, and Natural Computing with focus on developing graph and string algorithms for systems biology, advanced data structures for sequence analysis, distance measures for biological sequences, and machine learning applications in biomedical contexts. Avesani is actively involved in the Algorithmic Bioinformatics and Natural Computing research group where he applies theoretical methods to model biological information processes, as well as the InfOmics laboratory which specializes in efficient biomedical data analysis. Currently leading the project 'Defining Clinical and Molecular Phenotypes of Multi-Drug Resistance in difficult to treat Rheumatoid Arthritis - MDR-RA' (started January 1, 2025), his work develops novel methods for mining biological networks, integrating heterogeneous data, analyzing omics, reconstructing pangenomes, and patient classification using interdisciplinary approaches from machine learning, data science, mathematics, and graph theory. He is affiliated with the INFOMICS laboratory among several specialized research facilities including IRIS, ISLa, and STARS laboratories within the department.